Private health insurers covered the largest share of prescription drug costs, $140 billion, in 2017, according to a new Kaiser Family Foundation study.
Here is a breakdown of the 10 drugs employer-sponsored health plans paid the most for in 2017:
1. Humira ($4.9 billion)
2. Enbrel ($2.4 billion)
3. Copaxone ($1.2 billion)
4. Tecfidera ($1.1 billion)
5. Harvoni ($1 billion)
6. Truvada ($900 million)
7. Stelara ($900 million)
8. Vyvanse ($900 million)
9. Lantus Solostar ($800 million)
10. Gilenya ($700 million)
Read the full report here.